RxDoctor Payments DataLook up a doctor →

Derek Lewis, MD

Family Medicine · Little Rock, ARNPI 1407810641

Payments from drug & device makers

$1,703,660in general payments, 2019–2025

Across 898 payments — averaging $1897.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$603K
  • Valneva Austria GmbH$225K
  • Boehringer Ingelheim$180K
  • Bavarian Nordic A/s$180K
  • Seqirus USA Inc$176K
  • Novavax Inc$139K
  • plus $201K from 41 others
$100,957in research payments, 2019–2025

Across 2 payments — averaging $50,479 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Valneva Austria GmbH$101K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.418$602,712
Valneva Austria GmbH11$224,983
Boehringer Ingelheim25$180,170
Bavarian Nordic A/s45$180,127
Seqirus USA Inc75$175,772
Novavax Inc5$138,879
AstraZeneca7$26,897
Incyte Corporation20$26,541
Gilead5$18,433
Genentech, Inc.3$15,500
Boehringer Ingelheim International GmbH103$15,113
Amgen(2 entities)3$14,527
GSK22$13,892
Takeda Pharmaceuticals U.S.A., Inc.10$13,343
Sanofi-aventis U.S. LLC5$12,330
Global Blood Therapeutics, Inc.18$11,711
Sanofi US Services Inc.6$6,921
Eli Lilly1$6,231
Janssen Research & Development, LLC2$5,951
Novo Nordisk AS2$4,884
Lexicon Pharmaceuticals, Inc.1$3,155
Pfizer(2 entities)24$1,857
Novartis7$1,687
AbbVie(2 entities)11$276
Biotronik Inc.5$232
Lilly USA, LLC11$191
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)8$158
Johnson & Johnson6$157
Nevro Corp.8$129
Novo Nordisk3$128
MDD US Operations, LLC1$128
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$117
Amarin Pharma, Inc.1$116
Abbott1$98
Ferring Pharmaceuticals Inc.1$84
Esperion Therapeutics, Inc.4$54
Bayer2$30
Boston Scientific1$19
Dexcom, Inc.1$18
Astellas Pharma US Inc1$17
Sumitomo Pharma America, Inc.1$17
Kowa Pharmaceuticals America, Inc.1$14
Globus Medical1$14
Idorsia Pharmaceuticals US Inc1$13
Sanofi1$13
Impel Pharmaceuticals Inc.1$12
Biodelivery Sciences International, Inc.1$11

How this compares

$1,703,660 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas →

Medicare billing

Part B allowed, 2024
$104,175
Medicare patients
186
Services billed
1,792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Little Rock

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →